Call Us Sign-Up/Sign-In
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications



iCrowdNewswire   Jan 26, 2021  9:00 AM ET

Support for preclinical testing for a novel broad spectrum inhaled anti-infective that rapidly eradicates microbial biofilms which are present in the lungs of Cystic Fibrosis patients

DUBLIN,OHIO (26 January 2021) Kinnear Pharmaceuticals (Kinnear)announces an agreement with the Cystic Fibrosis Foundation on a staged Therapeutic Development Award (TDA) providing development funds for Kinnear’s lead compound, CSA-131. The staged award of up to $3 million, supported with matching funds from Kinnear, provides funding for preclinical research to enable the filing of an Investigational New Drug (IND) application with the FDA in 2022.

“We are pleased and honored to announce this agreement with the Cystic Fibrosis Foundation to help progress CSA-131 as a novel therapeutic drug candidate for CF lung infections. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-resistant bacteria and fungi that produce biofilms, including Pseudomonas aeruginosa. Even in the era of CFTR modulators, there is an urgent need for new anti-infective treatment approaches as the presence of infection reduces their efficacy. We believe that CSA-131 has promise to address one of the key factors that results in shortened life expectancy in CF patients,” said Carl Genberg, Chief Executive Officer of Kinnear Pharmaceuticals. “We have validated technology. There are now 20 peer reviewed journal articles on the potential use of CSA-131 for CF applications.”

About Cystic Fibrosis:

Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract.

About Kinnear:

Kinnear is a biotechnology company focused on the discovery and development of CSA-131 and other Ceragenins for the prevention and treatment of life-threatening, antibiotic-resistant infections in CF, gastrointestinal diseases, and multiple myeloma.

About Ceragenins:

This novel and patented class of compounds are synthetic non-peptide mimics of endogenous antimicrobial peptides (AMPs). AMPs are a key component of our body’s own innate immune system. Ceragenins have been shown to have excellent activity against multidrug resistant bacteria, fungi and most recently, the pandemic. CSA-131 has been successfully tested in humans as part of Kinnear’s parent company N8Medical’s research efforts for its CeraShield Endotracheal Tube (ETT). The ETT contains a coating incorporating CSA-131 as a preservative to prevent biofilm growth on the tube’s surfaces. Biofilms are aggregations of pathogenic cells that are highly resistant to conventional antibiotics. Over time, many CF patients develop bacterial and fungal biofilms biofilms in their lungs which destroy the elasticity of lung tissues ultimately leading to an inability to breathe.

Investor Relations Contacts:

Carl Genberg, CEO

Kinnear Pharmaceuticals, LLC

Tel: (702) 285-5740


Keywords:    Cystic Fibrosis, Biotech, Kinnear, Respiratory Infections, Inhaled Drug, Biofilm

Tags:    IPS, Google News, Financial Content, Extended Distribution, iCN Internal Distribution, English